(CercleFinance.com) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved its Type II variation application for Tecvayli® (teclistamab), providing the possibility of reduced dosing frequency 1.5 mg/kg every other week in patients who have achieved a complete response (CR) or better for at least six months.
Teclistamab is approved for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies.
“Today’s approval reinforces our commitment to strengthen our multiple myeloma portfolio by investing in cutting-edge research that will help us continue to improve patient outcomes and, most importantly, their quality of life,” said said Sen Zhuang, vice president of clinical research and development at Janssen Research & Development.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
